The biological basis for breast cancer screening and its relevance to treatment

Early Breast Cancer: From Screening to Multidisciplinary Management, Third Edition

Volumn , Issue , 2013, Pages 50-66

  Benson, John R ^a,b,c  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c ANGLIA RUSKIN UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84992362656     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b13937     Document Type: Chapter

References (189)

1. Wilson JMG, Junger G. Principles and Practice of Screening for Disease (Public Health Paper No.34). Geneva: World Health Organisation, 1968.
2. Jatoi I, Anderson WF. Cancer screening. Curr Probl Surg 2005; 42: 620-82.
3. Cole P, Morrison AS. Basic issues in population screening for cancer. J Natl Cancer Inst 1980; 64: 1263-72.
4. Shapiro S, Venet W, Strax P, Venet L, Roeser R. Ten-to fourteen-year effect of screening on breast cancer mortality. J Natl Cancer Inst 1982; 69: 349.
5. Tabar L, Fagerberg CJG, Gad A, et al. Reduction in mortality from breast cancer after mass screening with mammography. Lancet 1985; 1: 829-32.
6. Fletcher SW, Black W, Harris R, et al. Report of the international workshop on screening for breast cancer. J Natl Cancer Inst 1993; 85: 1644-56.
7. Nystrom L, Rutqvist LE, Walls S, et al. Breast screening with mammography: overview of Swedish randomised trials. Lancet 1993; 341: 973-8.
8. Vainio H, Bianchini F, eds. IARC Handbook of Cancer Prevention. Breast Cancer Screening. Vol 7 Lyon, France: IARC Press, 2002.
9. NIH Consensus Statement. Breast cancer screening for women ages 40-49. NIH Consensus Statement 1997.
10. Gotzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2006; 3: CD001877.
11. Kerlikowske K, Grady D, Rubin SM, Sandrock C, Ernster VL. Efficacy of screening mammography. A meta-analysis. JAMA 1995; 273: 149-54.
12. Duffy SW, Tabar L, Smith RA. The mammographic screening trials: commentary on the recent work by Olsen and Gotzsche. CA Cancer J Clin 2002; 52: 68-71.
13. US Preventive Services Task Force. Screening for breast cancer: US preventive services task force recommendation statement. Ann Int Med 2009; 151: 716-26.
14. Moss SM, Cuckle H, Evans A, et al. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years’ follow-up: a randomised controlled trial. Lancet 2006; 368: 2053-60.
15. Thomas DB, et al. Randomised trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst 2002; 94: 1445-57.
16. Moss SM. Breast cancer screening. Br J Hosp Med 1992; 48: 178-81.
17. Spratt JA, von Fournier D, Spratt JS, Weber E. Mammographic assessment of human breast cancer growth and duration. Cancer 1993; 71: 2020-6.
18. Wette R, Katz IN, Rodin EY. Stochastic processes for solid tumor kinetics: I. surface regulated growth. Math Biosciences 1974; 19: 231-55.
19. Spratt JS, Greenberg RA, Heuser LS. Geometry, growth rates and duration of cancer and carcinoma in situ of the breast before detection by screening. Cancer Res 1986; 46: 970-4.
20. Speer JF, Petrosky VE, Retsky MW, Wardwell RH. A stochastic numerical model of breast cancer growth that stimulates clinical data. Cancer Res 1984; 44: 4124-30.
21. Holmberg L, Ekbom A, Zack M. Do screen-detected invasive breast cancers have a natural history of their own? Eur J Cancer 1992; 28A: 920-3.
22. Jatoi I. Breast cancer: a systemic or local disease? Am J Clin Oncol 1997; 20: 536-9.
23. Hellman S. Natural history of small breast cancers. J Clin Oncol 1994; 12: 2229-34.
24. Virchow R. Cellular Pathology. Translated from the 2nd German Edition by F. Chance Philadelphia: Lippincott, 1863.
25. Virchow R. Die Krankhaften Geschwulste, 3 volumes Berlin, A. Hirschwald, 1863-1873 Vol, 26-27.
26. Halsted WS. The radical operation for the cure of carcinoma of the breast. Johns Hopkins Hosp Rep 1898; 28: 557.
27. Halsted WS. The results of operations for the cure of cancer of the breast performed at The Johns Hopkins Hospital from June, 1889 to January, 1894. Johns Hopkins Hospital Reports 1894; 5; 4: 297-350.
28. Baum M. The history of breast cancer. In: Forbes JF, ed. Breast Disease. Edinburgh: Churchill Livingston, 1986: 95-105.
29. Brinkley D, Haybittle JL. The curability of breast cancer. Lancet 1973; 2: 95-8.
30. Fisher B. Laboratory and clinical research in breast cancer-a personal adventure: the David A. Karnofsky memorial lecture. Cancer Res 1980; 40: 3863-74.
31. Fisher B, Fisher ER. Transmigration of lymph nodes by tumour cells. Science 1966; 152: 1397-8.
32. Fisher B, Fisher ER. Barrier function of lymph node to tumour cells and erythrocytes I. Normal nodes. Cancer 1967; 20: 1907-13.
33. Fisher B, Fisher ER. Barrier function of lymph node to tumour cells and erythrocytes II. Effect of X-ray, inflammation, sensitisation and tumour growth. Cancer 1967; 20: 1914-19.
34. Baum M, Benson JR. Current and future roles of adjuvant endocrine therapy in management of early carcinoma of the breast. In: Senn H-J, Goldhirsch RD, Gelber RD, Thurlimaan B, eds. Recent Results in Cancer Research 140-Adjuvant Therapy of Breast Cancer. Berlin: Heidelberg, New York: Springer-Verlag, 1996: 215-26.
35. Atkins H, Hayward JL, Klugman DJ, Wayte AB. Treatment of early breast cancer: a report after 10 years of a clinical trial. Br Med J 1972; 2: 423-9.
36. Fisher B, Redmond C, Poisson R, et al. Eight year results of a randomised clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. NEJM 1989; 320: 822-7.
37. Veronesi U, Saccozzi R, Del Vecchio M, et al. Comparing radical mastectomy with quadrantectomy, axillary dissection and radiotherapy in patients with small cancers of the breast. NEJM 1981; 305: 6-11.
38. Sarrazin D, Dewar JA, Arriagada R, et al. Conservative management of breast cancer. Br J Surg 1986; 73: 604-6.
39. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow up of a randomized trial comparing total mastectomy, lumpectomy and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347: 1233-41.
40. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow up of a randomized study comparing breast conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002; 347: 1227-32.
41. Litiere S, Werutsky G, Fentiman IS, et al. Breast-conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol 2012; 13: 412-19.
42. Early Breast Cancer Trialists Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15 year survival: an overview of the randomized trials. Lancet 2005; 366: 2087-106.
43. Benson JR. Long-term outcome of breast conserving surgery. Lancet Oncol 2012; 13: 331-3.
44. Benson JR, Teo K. Breast cancer local therapy: what is it’s effect on mortality? World J Surg 2012; 36: 1460-74.
45. Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998; 351: 1451-61.
46. Hacksaw A, Roughton M, Forsyth S, et al. Long term benefits of 5 years of tamoxifen: 10 year follow up of a large randomized trial in women at least 50 years of age with early breast cancer. J Clin Oncol 2011; 29: 1657-67.
47. Early Breast Cancer Trialists’ Colloborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 1998; 352: 930-42.
48. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155-68.
49. Davies C, Godwin J, Gray R, et al. Early Breast Cancer Trialists’ Colloborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patientlevel meta-analysis of randomized trials. Lancet 2011; 378: 771-84.
50. Howell A, Cuzick J, Baum M, et al. Results of the ATAC Arimidex, Tamoxifen Alone or in Combination. Trial after completion of 5 years adjuvant treatment for breast cancer. Lancet 2011; 378: 771-84.
51. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-92.
52. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group. Forbes JF, Cuzik J, Buzdar A, et a. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: a 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9: 45-53.
53. Mourisden H, Giobbie-Hurder A, Goldhirsch A, et al. BIG 1-98 Colloborative Group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009; 361: 766-76.
54. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in post-menopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-802.
55. Davidson NE, Morrow M. Sometimes a great notion-an assessment of neoadjuvant systemic therapy for breast cancer. J Natl Cancer Inst 2005; 97: 159-61.
56. Wolff AC, Davidson NE. Primary systemic therapy in operable breast cancer. J Clin Oncol 2000; 18: 1558-69.
57. Bonadonna G, Valagussa P, Bramnilla C, et al. Primary chemotherapy in operable breast cancer: eight year experience at the Milan Cancer Institute. J Clin Oncol 1998; 16: 93-100.
58. Smith IE, Walsh G, Jones A, et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 1995; 13: 424-9.
59. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment for breast cancer: a meta-analyis. J Natl Cancer Inst 2005; 97: 188-94.
60. Haybittle JL. Curability of breast cancer. Br Med Bull 1990; 47: 319-23.
61. Berkson J, Harrington SW, Clagett OT, et al. Mortality and Survival in surgically treated breast caner: a statistical summary of some experience of the Mayo Clinic. Proc Staff Meetings Mayo Clinic 1957; 32: 645.
62. Brinkley D, Haybittle JL. Long-term survival of women with breast cancer. Lancet 1984; 1: 1118.
63. Le MG, Hill C, Rezvani A, et al. Long-term survival of women with breast cancer. Lancet 1984; 2: 922.
64. Langlands AO, Pocock SJ, Kerr GR, Gore SM. Long-term survival of patients with breast cancer: a study of the curability of the disease. Br Med J 1979; 2: 1247-51.
65. Adair F, Berg J, Lourdes J, Robbins GF. Long-term follow up of breast cancer patients: The 30-year report. Cancer 1974; 33: 1145-50.
66. Hayward J, Caleffi M. The significance of local control in the primary treatment of breast cancer. Arch Surg 1987; 122: 1244.
67. Rosen PP, Groshen S, Saigo PE, et al. A long term follow up study of survival in stage I (T1N1M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol 1989; 7: 355-66.
68. Sigurdsson H, Baldetorp B, Borg A, et al. Indicators of prognosis in node-negative breast cancer. N Engl J Med 1990; 322: 1045-53.
69. Folkman J. What is the evidence that tumours are angiogenesis dependent ? J Natl Cancer Institute 1990; 82: 4-6.
70. Pickren JW. Significance of occult metastases. Cancer 1961; 14: 1266-71.
71. Fisher ER, Swamidoss S, Lee CH, et al. Detection and significance of occult axillary node metastases in patients with invasive breast cancer. Cancer 1978; 45: 2025-31.
72. de Mascerel I, Bonichon F, Coindre JM, Trojani M. Prognostic signifi-cance of breast cancer axillary lymph node micro-metastases assessed by two special techniques: re-evaluation with longer follow up. Br J Cancer 1992; 66: 303-6.
73. Trojani M, de Mascarel I, Bonichon F, et al. Micro-metastases to axillary lymph nodes from carcinoma of breast: detection by immunohistochemistry and prognostic significance. Br J Cancer 1987; 55: 303-6.
74. International Ludwig Breast Cancer Study Group. Prognostic importance of occult axillary lymph node micrometastases from breast cancer. Lancet 1990; 335: 1565-8.
75. Hansen NM, Grube B, Ye X, et al. Impact of micrometastases in the sentinel lymph node of patients with invasive breast cancer. J Clin Oncol 2009; 27: 4679-84.
76. Weidner N, Semple JP, Welch WR, Folkman J. Tumour angiogenesis and metastasis-correlation in invasive breast carcinoma. NEJM 1991; 324: 1-8.
77. Liotta L, Kleinerman J, Saidel G. Quantitative relationships of intravascular tumour cells, tumour vessels and pulmonary metastases following tumor implantation. Cancer Res 1974; 34: 997-1004.
78. Rosfjord EC, Dickson RB. Role of integrins in the development and malignancy of the breast. In: Bowcock A, ed. Breast Cancer: Molecular Genetics, Pethogenesis and Therapeutics. Chapter 13 New Jersey: Humana Press, 1999: 285-304.
79. Duffy SW, Tabar L, Fagerberg G, et al. Breast screening, prognostic factors and survival-results from the Swedish two county study. Br J Cancer 1991; 64: 1133-8.
80. Hakama M, Holli K, Isola J, et al. Aggressiveness of screen-detected breast cancer. Lancet 1995; 345: 221-4.
81. Fagerberg CJG, Baldetorp L, Grontoft O, et al. Effects of repeated mammographic screening on breast cancer stage distribution. Acta Radiol Oncol 1985; 24: 465.
82. Tabar L, Duffy SW, Krusemo UB. Detection method, tumour size and node metastases in breast cancers diagnosed during a trial of breast cancer screening. Eur J Cancer 1987; 23: 959-62.
83. Baker LH. Breast cancer detection demonstration project: five-year summary report. CA Cancer J Clin 1982; 32: 194-225.
84. Fisher B, et al. Surgical adjuvant chemotherapy in cancer of the breast. Results of a decade of co-operative investigation. Ann Surg 1968; 168: 337-56.
85. Salvadori B, et al. Prognostic factors in operable breast cancer. Tumori 1983; 69: 477-84.
86. Mamounas EP, Tang G, Fisher B, et al. Association between the 21-gene recurrence score assay and risk of loco-regional recurrence in node negative, estrogen receptor positive breast cancer: results from NSAPBP B-14 and NSABP B-20. J Clin Oncol 2010; 28: 1677-83.
87. Voduc KD, Cheang MCU, Tyldesley S, et al. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010; 28: 1684-91.
88. Carter CL, Allen C, Henderson DE. Relation of tumour size, lymph node status and survival in 24, 740 breast cancer cases. Cancer 1989; 73: 505-8.
89. Fisher B, Slack NH, Bross IDJ, et al. Cancer of the breast: size of neoplasm and prognosis. Cancer 1969; 24: 1071-80.
90. Haagensen CD. Diseases of the Breast, 3rd edn. Philapdelphia: Saunders, 1986: 659.
91. Nemoto T, Vanna J, Bedwani RN, et al. Management and survival of female breast cancer: results of a national survey by the American college of surgeons. Cancer 1984; 45: 2917-24.
92. Tabar L, Fagerberg CJG, South MC, Duffy SW, Day NE. The Swedish Two County Trial of mammographic screening for breast cancer: recent results on mortality and tumour characteristics. In: Miller AB, Chamberlain J, Day NE, Hakama M, Prorok P, eds. Screening for Cancer. Bern: Hans Huber, 1991.
93. Tabar L, Duffy SW, Krusemo UB. Detection method, tumour size and node metastases in breast cancers diagnosed during a trial of breast cancer screening. Eur J Cancer Clin Oncol 1987; 23: 959-62.
94. Hatschek T, Fagerberg G, Olle S, et al. Cytometric characterisation and clinical course of breast cancer diagnosed in a population-based screening program. Cancer 1989; 64: 1074-81.
95. Anderson TJ, Lamb J, Donnan P, et al. Comparative pathology of breast cancer in a randomised trial of screening. Br J Cancer 1991; 64: 108-13.
96. Cole P, Morrison AS. Basic issues in population screening for cancer. J Natl Cancer Inst 1980; 64: 1263-72.
97. Crisp WJ, Higgs MJ, Cowan WK, et al. Screening for breast cancer detects tumours at an earlier biological stage. Br J Surg 1993; 80: 863-5.
98. Abernathy CM, Hedegaard H, Weger N. Screening for breast cancer detects tumours at an earlier biological stage (letter). Lancet 1994; 81: 922.
99. Bull A, Mountney L, Sanderson H. Stage distribution of breast cancer: a basis for the evaluation of breast screening programmes. Br J Radiol 1991; 64: 516-19.
100. Boyd NF, Jensen HM, Cooke G, Lee Han H. Relationship between mammographic and histological risk factors for breast cancer. J Natl Cancer Inst 1992; 1170-9.
101. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-52.
102. Klemi PJ, Joensuu H, Toikkanen J, et al. Aggressiveness of breast cancers found with and without screening. Br Med J 1992; 304: 467-9.
103. Bennet IC, McCaffrey JF, Baker CA, et al. Changing patterns in the presentation of breast cancer over 25 years. Aust NZ J Surg 1990; 60: 665-71.
104. Rajakariar R, Walker RA. The biological nature of screen-detected invasive breast cancer (meeting abstract). J Path 1993; 170(Suppl): 387A.
105. Day NE. Screening for breast cancer. Br Med Bull 1991; 47: 400-15.
106. Shen Y, Yang Y, Innoue LY, et al. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst 2005; 97: 1195-203.
107. Joensuu H, Lehtimaki T, Holli K, et al. Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA 2004; 292: 1064-73.
108. Mook S, Van’t Veer LJ, Rutgers E, et al. Independent prognostic value of screen detection in invasive breast cancer. J Natl Cancer Inst 2005; 97: 1195-203.
109. Wishart GC, Greenberg DC, Britton PD, et al. Screen-detected versus asymptomatic breast cancer: is improved survival due to stage migration alone? Br J Cancer 2008; 98: 1741-4.
110. Dawson SJ, Duffy SW, Blows FM, et al. Molecular characteristics of screen-detected versus symptomatic breast cancer and their impact on survival. Br J Cancer 2009; 101: 1338-44.
111. Brown SBF, Mallon EA, Edwards J, et al. Is the biology of breast cancer changing? A study of hormone receptor status1984-1986 and 1996-1997. Br J Cancer 2009; 100: 807-10.
112. Jatoi I, Anderson WF. Aggressiveness of breast cancers found with and without screening. Br Med J 1992; 304: 467-9.
113. Nicholson S, Webb AJ, Coghlan B, et al. Will screening for breast cancer reduce mortality ? Evidence from the first year of screening in Avon. Ann Roy Coll Surg 1993; 75: 8-12.
114. Wicks K, Fisher CJ, Fentimen IS, Millis RR. Breast cancer histology and age (meeting abstract). J Pathol 1992; 167(Suppl): 139A.
115. Fisher B, Saffer E, Fisher ER, Studies concerning the regional nodes in cancer IV. Tumour inhibition by regional lymph node cells. Cancer 1974; 33: 631-6.
116. Fisher B, Saffer E, Fisher ER, Studies concerning the regional nodes in cancer VII. Thymidine uptake by cells from nodes of breast cancer patients. Cancer 1974; 33: 271-9.
117. Ponten J, Holmberg L, Trichopoulos D. Biology and natural history of breast cancer. Int J Cancer 1990; 5: 1-21.
118. Meyer JS, Witliff JL. Regional heterogeneity in breast carcinoma: thymidine labelling index, steroid hormone receptors, DNA ploidy. Int J Cancer 1991; 47: 213.
119. Anderson TJ, Lamb J, Alexander F, et al. Comparative pathology of prevalent and incident cancer detected by breast screening. Edinburgh Breast Screening Project. Lancet 1986; 1: 519-23.
120. Brewster AM, Thompson P, Sahin AA, et al. Copy number imbalances between screen-detected and symptom-detected breast cancers and impact on disease-free survival. Cancer Prev Res 2011; 4: 1609-16.
121. Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive pre-menopausal women with breast cancer. N Engl J Med 1997; 337: 956-62.
122. Overgaard M, Hansen PS, Overgaard J, et al. Post-operative radiotherapy in high risk pre-menopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med 1997; 337: 949-55.
123. Hellman S. Stopping metastases at their source (editorial). N Engl J Med 1997; 337: 996-7.
124. Salmon S. Kinetic rationale for adjuvant chemotherapy of cancer. In: Salmon S, Jones S, eds. Adjuvant Chemotherapy of Cancer. Amsterdam: Elsevier/North-Holland Biomedical Press, 1977: 15-27.
125. Skipper H, Schabel F Jr. Quantitative and cytokinetic studies in experimental tumor systems. In: Holland JF, Frei E III, eds. Cancer Medicine, 2nd edn. Philadelphia: Lea and Febiger, 1982: 636-48.
126. Heuser L, Spratt JS, Polk HC Jr. Growth rates of primary breast cancers. Cancer 1979; 43: 1888-94.
127. Gillilard FD, Joste N, Stauber PM, et al. Biological characteristics of interval and screen-detected cancers. J Natl Cancer Inst 2000; 92: 743-9.
128. Moskowitz M. Breast Cancer: age specific growth rates and screening strategies. Radiology 1986; 161: 37-41.
129. Holland R, Mravunac M, Hendriks JHCL, Bekekr BV. So-called interval cancers of the breasts: pathologic and radiologic analysis of sixty four cases. Cancer 1982; 49: 2527-33.
130. Heuser L, Spratt JS, Polk HC Jr, Buchanan J. Relation between mammary cancer growth kinetics and the intervals between screenings. Cancer 1979; 43: 857-62.
131. Woodman CBJ, Threlfall AG, Boggis CRM, Prior P. Is the three year breast screening interval too long? Occurrence of interval cancers in NHS screening programme’s northwestern region. BMJ 1995; 310: 224-6.
132. Martin JE, Moskowitz M, Milbrath JR. Breast cancer missed by mammography. Am J Roentgenol 1979; 132: 737-9.
133. Holland R, Hendriks JH, Mravunac M. Mammographically occult breast cancer. A pathologic and radiologic study. Cancer 1983; 52: 1810-19.
134. Frisell J, Eklund G, Hellstrom L, Somell A. Analysis of interval breast carcinomas in a randomised screening trial in Stockholm. Breast Cancer Res Treat 1987; 9: 219-25.
135. Ma L, Fishell J, Wright B, et al. Case-control study of factors associated with failure to detect breast cancer by mammography. J Natl Cancer Inst 1992; 84: 781-5.
136. Ikeda D, Andersson I, Wattsgard C, Janzon L, Linell F. Interval cancers in the Malmo Mammographic Screening Trial: radiographic appearance and prognostic considerations. Am J Roentgenol 1992; 159: 287-94.
137. Heuser LS, Spratt JS, Kuhns JG, et al. The association of pathologic and mammographic characteristics of primary human breast cancers with “slow” and “fast” growth rates and with axillary lymph node metastases. Cancer 1984; 53: 96-8.
138. Porter PL, El-Bastawissi AY, Mandelson MT, et al. Breast tumor characteristics as predictors of mammographic detection: comparison of interval and screen-detected cancers. J Natl Cancer Inst 1999; 91: 2020-8.
139. Brekelmans CT, van Gorp JM, Peeters PH, Collette HJ. Histopathology and growth rate of interval breast carcinoma. Characterization of different subgroups. Cancer 1996; 78: 1220-8.
140. Frisell J, von Rosen A, Wiege M, Nilsson B, Goldman S. Interval cancer and survival in a randomised breast cancer screening trial in Stockholm. Breast Cancer Res Treat 1992; 24: 11-16.
141. Klemi PJ, Toikkanen S, Rasanen O, Parvinen I, Joensuu H. Mammography screening interval and the frequency of interval cancers in a population-based screening. Br J Cancer 1997; 75: 762-6.
142. Hatschek T, Fagerberg G, Stal O, et al. Cytometric characterization and clinical course of breast cancer diagnosed in a population-based screening program. Cancer 1990; 64: 1074-81.
143. Gilliland FD, Joste N, Stauber PM, et al. Biologic characteristics of interval and screen-detected breast cancers. J Natl Cancer Inst 2000; 92: 743-9.
144. Arnerlov C, Emdin SO, Lundgren B, et al. Breast carcinoma growth rate described by mammographic doubling time and S-phase fraction. Correlations to clinical and histopathologic factors in a screened population. Cancer 1992; 70: 1928-34.
145. Narod SA. Dube M-P Biologic characteristics of interval and screendetected breast cancers (correspondence). J Natl Cancer Inst 2001; 93: 151.
146. Andersson I, Aspegren K, Janzon L, et al. Effect of mammographic screening on breast cancer mortality in an urban population in Sweden. Results fro the Malmo mammographic screening trial (MMST). Br Med J 1988; 297: 943-8.
147. Vitak B. Invasive interval cancers in the ostergotland mammographic screening programme: radiological analysis. Eur Radiol 1998; 8: 639-46.
148. Day N, McCann J, Camilleri-Ferrante C, et al. Monitoring interval cancers in breast screening programmes: the East Anglian experience. Quality assurance Management Group of the East Anglian Breast Screening Programme. J Med Screen 1995; 2: 180-5.
149. Roberts MM, Alexander FE, Anderson TJ, et al. Edinburgh trial of screening for breast cancer: mortality at seven years. Lancet 1990; 335: 241-6.
150. Surveillance, Epidemiology and End Results SEER. Program Cancer Statistics Review (1973 -1995). Bethesda, MD, National Cancer Institute, Division of Cancer Prevention and Control, Surveillance Program, Cancer Statistics Branch, 1998 UPDATED REF.
151. Rosen PP, Braun DW, Kinne DE. The clinical significance of pre-invasive breast cancer. Cancer 1980; 46: 919-25.
152. Anderson J, Nielsen M, Christensen L. New aspects of the natural history of in situ and invasive carcinoma in the female breast: results from autopsy investigations. Verh Dtsch Ges Pathol 1985; 69: 88-95.
153. Welch HG, Black WC. Using autopsy series to estimate the disease “reservoir” for ductal carcinoma in situ of the breast: How much more breast cancer can we find ? Ann Intern Med 1997; 127: 1023-8.
154. Anderson TJ. Genesis and source of breast cancer. Brit Med Bull 1991; 47: 305-18.
155. Kerlikowski K, Salzman P, Philips KA, et al. Continuing screening mammography in women aged 70-79 years: impact on life expectancy and cost-effectiveness. JAMA 1999; 282: 2156-63.
156. Satariano WA, Ragland DR. The effect of co-morbidity on 3 year survival of women with primary breast cancer. Ann Intern Med 1994; 120: 104-10.
157. Welch HG, Black WC. Using autopsy series to estimate the disease ‘reservoir’ for ductal carcinoma in situ of the breast: How much more breast cancer can we find? Ann Int Med 1997; 127: 1023-8.
158. Gotzsche PC, Olsen O. Is screening for breat cancer with mammography justifiable? Lancet 2000; 355: 129-34.
159. Gotzsche PC, Hartling OJ, Nielsen M, Brodersen J, Jorgensen KJ. Breast screening, the facts-or maybe not. BMJ 2009; 338: 446-8.
160. Duffy SW, Tabar L, Olsen A, et al. Absolute numbers of lives saved and overdiagnosis in breast cancer screening, from a randomized trial and from the breast screening programme in England. J Med Screen 2010; 17: 25-30.
161. Benson JR. Will ductal carcinoma in situ defeat breast cancer screening? BMJ 2009; 338: 615.
162. Zahl PH, Maehlen J, Welch HG. The natural history of invasive breast cancers detected by screening mammography. Arch Intern Med 2008; 168: 2311-16.
163. Jatoi I, Anderson WF. Breast cancer overdiagnosis with screening mammography. Arch Int Med 2009; 169: 999-1000.
164. Benson JR, Purushotham A, Warren R. Screening and litigation-The rate of interval cancers is too high. BMJ 2000; 321: 760-1.
165. Kerlikowski K, Grady D, Barclay J, Sickles EA, Ernster V. Effect of age, breast density and family history on the sensitivity of first screening mammography. JAMA 1996; 276: 33-8.
166. Tabar L, Fagerberg G, Chen HH, Duffy SW, Gad A. Screening for breast cancer in women aged under 50: mode of detection, incidence, fatality and histology. J Med Screen 1995; 2: 94-8.
167. Chang J, Yang WT, Choo HF. Mammography in Asian patients with BRCA-1 mutations. Lancet 1999; 353: 2070-1.
168. Phillips KA, Andrulis IL, Goodwin PJ. Breast carcinomas arising in carriers of mutations in BRCA-1 and BRCA-2: are they prognostically different ? J Clin Oncol 1999; 17: 3653-63.
169. Phillips KA. Biologic characteristics of interval and screendetected breast cancers (correspondence). J Natl Cancer Inst 2001; 93: 151-2.
170. Saslow D, Boetes C, Burke W, et al. American cancer society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007; 57: 75-89.
171. Sterns EE, Zee B. Mammographic density changes in perimenopausal and postmenopausal women: is effect of hormone replacement therapy predictable? Breast Cancer Res Treat 2000; 59: 125-32.
172. Litherland JC, et al. The effect of hormone replacement therapy in the sensitivity of screening mammography. Clin Radiol 1999; 54: 285-8.
173. Roussouw JE, Anderson GL, Prentice RL, et al. Writing group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
174. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast cancer incidence in 2003 in the United States. N Engl J Med 2007; 356: 1670-4.
175. Desantis C, Howlader N, Cronin KA, et al. Breast cancer incidence rates in US women are no longer declining. Cancer Epidemiol Biomarkers Prev 2011; 20: 733-9.
176. Zahl PH, Maehlen JA. A decline in breast cancer incidence. N Engl J Med 2007; 357: 509-13.
177. Elfenbein GJ. A decline in breast cancer incidence. N Engl J Med 2007; 357: 509-13.
178. Sankaranarayanan R, Ramadas K, Thara S, et al. Clinical breast examination: preliminary results from a cluster randomized controlled trial in India. J Natl Cancer Inst 2011; 103: 1476-80.
179. Shapiro S. Periodic screening for breast cancer: the HIP Randomised Controlled Trial. Health Insurance Plan. J Natl Cancer Inst Monogr 1997; 22: 27-30.
180. Jatoi I. The impact of advances in treatment on the efficacy of mammography screening. Prev Med 2011; 53: 103-4.
181. Rostgaard K, Vaeth M, Rootzen H, et al. Why did the breast cancer lymph node status distribution improve in Denmark in the pre-mammography screening period o. 1978-1994? Acta Oncol 2010; 49: 313-21.
182. Jatoi I, Proschan MA. Clinical trial results applied to management of the individual cancer patient. World J Surg 2007; 30: 1184-9.
183. Kalager M, Zelen M, Langmark F, et al. Effect of screening mammography on breast cancer mortality in Norway. N Engl J Med 2010; 363: 1203-10.
184. Lord SJ, Irwig L, Simes RJ. When is measuring sensitivity and specificity sufficient to evaluate a diagnostic test, and when do we need randomized trials? Ann Intern Med 2006; 144: 850-5.
185. Duffy SW. Interpretation of the breast screening trials: a commentary on the recent paper by Gotzsche and Olsen. Breast 2001; 10: 209-12.
186. Baum M. Screening for breast cancer, time to think-and stop ? Lancet 1995; 346: 436.
187. Querci della Rovere G, Benson JR, Warren R. Screening for breast cancer, time to think-and stop? Lancet 1995; 346: 437.
188. Baum M. Commentary: false premises, false promises and false positives-the case against mammographic screening for breast cancer. Int J Epidemiol 2004; 33: 66-7.
189. Gotzsche PC, Hartling OJ, Nielsen M, Brodersen J, Jorgensen KJ. Breast screening, the facts-or may be not. BMJ 2009; 338: 446-8.